¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Alpha heavy chain disease"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
¿µ¹® Behcet disease ÇÑ±Û º£Ã¼Æ®º´
¼³¸í   
  ½ÉÇÑ Æ÷µµ¸·¿°, ¸Á¸·Ç÷°ü¿°, ½Ã°¢½Å°æÀ§Ãà, ±¸°­-¼º±âÀÇ ¾ÆÇÁŸ¼º ±Ë¾ç, ±¤¹üÀ§ÇÑ Ç÷°ü¿°ÀǠ¡ÈĿ͠Áõ»óÀ» ³ªÅ¸³½´Ù. ¿øÀκҸíÀÇ Èñ±ÍÇÑ º´À¸·Î ÀþÀº ³²ÀÚ¿¡°Ô Àß ¹ß»ýÇÑ´Ù.
¿µ¹® congenital heart disease ÇÑ±Û ¼±Ãµ½ÉÀ庴
¼³¸í   
  ¼±ÃµÀûÀ¸·Î ½ÉÀåÀÇ ±¸Á¶¿¡ ÀÌ»óÀÌ Àִ º´.
¿µ¹® venereal disease, sexually transmitted diseases ÇÑ±Û ¼ºº´
¼³¸í   
  º¸ÆíÀûÀ¸·Î ¼º±³ ¶Ç´Â ¼º±âÁ¢ÃË¿¡ ÀÇÇØ °É¸®´Â Á¢ÃË Àü¿°º´À¸·Î ¸Åµ¶, ÀÓÁú, ¹«¸¥±Ë¾ç, »ô±¼À°¾ÆÁ¾ µîÀ» ¸»ÇÑ´Ù. Ä¡·á´Â ¿øÀαտ¡ µû¸¥ ÀûÀýÇÑ Ç×»ý¿ä¹ýÀÌ´Ù.
¿µ¹® VDRL(venereal disease research laboratory) ÇÑ±Û ¼ºº´ ¿¬±¸½ÇÇè½Ç
¼³¸í   
  ¸Åµ¶±ÕÀÇ reagin¿¡ ´ëÇÑ Ç×ü. ¸Åµ¶ÀÇ ¼±º°°Ë»ç·Î »ç¿ëµÇ¸ç ¸Åµ¶ Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀ ¿©ºÎ¿Í Ä¡·áÈ¿°ú ÆÇÁ¤¿¡µµ »ç¿ëµÈ´Ù. ¸Åµ¶¿Ü¿¡µµ Àü½Å¼ºÈ«¹Ý¼º³¶Ã¢, ·ù¸¶Æ¼½º°üÀý¿° µî¿¡¼­µµ ¾ç¼ºÀ¸·Î ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
¿µ¹® hemolytic disease of newborn ÇÑ±Û ½Å»ý¾Æ¿ëÇ÷º´
¼³¸í   
  ½Å»ý¾Æ¿¡¼­ ÀûÇ÷±¸°¡ ºñÁ¤»óÀûÀ¸·Î ¸¹ÀÌ ÆÄ±«µÇ´Â º´À¸·Î Å¾ÆÀû¸ð±¸Áõ(erythroblastosis fetalis)¿Í °°Àº ¶æÀ¸·Î ¾²ÀδÙ. À̰ÍÀº ¾î¸Ó´Ï¿¡°Ô¼­ »ý»êµÈ ½Å»ý¾Æ³ª Å¾ÆÀÇ ÀûÇ÷±¸¿¡ ´ëÇÑ Ç×ü°¡ Å¹ÝÀ» °Ç³Ê¿Í¼­ Å¾ÆÀÇ ÀûÇ÷±¸¿Í °áÇÕÇÏ¿©¼­ »ý±â´Â ¿ëÇ÷¼ººóÇ÷À» À̸£´Â ¸». ÁŻý¾Æ³ª Å¾ÆÀÇ ÀûÇ÷±¸ÀÇ Ç×ü°¡ ¾î¸Ó´ÏÀÇ ¸ö¿¡¼­ »ý»êÀÌ µÇ°í À̰ÍÀ̠ŹÝÀ» ÅëÇØ¼­ Å¾ƿ¡°Ô ³Ñ¾î°¡¼­ Å¾ÆÀÇ ÀûÇ÷±¸¿Í °áÇÕÀ» Çϰí ÀÌ Ç×ü¿Í °áÇÕÇÑ ÀûÇ÷±¸´Â ÆÄ±«°¡ µÇ¾î¼­ ºóÇ÷ÀÌ »ý±ä °ÍÀ» Å¾ÆÀû¸ð±¸ÁõÀ̶ó°í ÇÑ´Ù. À̰ÍÀº Rh Àû¸ð±¸Áõ(Rh erythroblastosis)¿Í ABO Àû¸ð±¸Áõ(ABO erythroblastosis)·Î ³ª´­ ¼ö°¡ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • chain cystourethrography
    »ç½½¹æ±¤¿äµµÁ¶¿µ(¼ú)
  • chain fiber
    Çٻ罽¼¶À¯, Çٻ罽±ÙÀ°¼¼Æ÷
  • chain initiation reaction
    ¿¬¼â°³½Ã¹ÝÀÀ
  • chain reaction
    ¿¬¼â¹ÝÀÀ
  • chain saw
    »ç½½Åé
  • chain termination method
    »ç½½Á¾·á¹ý, ¿¬¼âÁ¾·á¹ý
  • chromosome chain
    ¿°»öü»ç½½, ¿°»öü°í¸®
  • food chain
    ¸ÔÀ̻罽
  • hemolytic chain
    ¿ëÇ÷»ç½½
  • joining chain
    ¿¬°á»ç½½
  • lateral chain
    °ç»ç½½
  • light chain
    °¡º­¿î»ç½½, °æ¼â
  • light-chain nephropathy
    °¡º­¿î»ç½½ÄáÆÏº´(Áõ), °æ¼â½ÅÀ庴(Áõ)
  • nuclear chain
    Çٻ罽
  • nuclear chain fiber
    Çٻ罽¼¶À¯, Çٻ罽±Ù(À°)¼¼Æ÷
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • life style disease
    »ýȰ½À°üº´
  • metabolic disease
    ´ë»çº´, ´ë»çÁúȯ
  • mixed connective tissue disease
    È¥ÇÕ°áÇÕÁ¶Á÷º´
  • moyamoya disease
    ¸ð¾ß¸ð¾ßº´
  • muscle disease
    ±ÙÀ°º´
  • Osgood-Schlatter disease
    (¢¡ osteochondrosis of the tuberosity of the tibia) ¿À½º±Â½¶¶óÅͺ´, Á¤°­»À°ÅÄ£¸é»À¿¬°ñÁõ
  • Paget's disease
    ÆÄÁ¦Æ®º´
  • Parkinson's disease
    ÆÄŲ½¼º´
  • pelvic inflammatory disease
    °ñ¹Ý³»°¨¿°
  • pneumatic hammer disease
    ¾ÐÂø°ø±âÇØ¸ÓÁõ
  • primary cholestatic liver disease
    ÀÏÂ÷¾µ°³ÁóÁ¤Ã¼°£Áúȯ, ÀÏÂ÷´ãÁóÁ¤Ã¼°£Áúȯ
  • professional disease
    Á÷¾÷º´
  • Raynaud¡¯s disease
    ·¹À̳뺴
  • renal disease
    ÄáÆÏº´, ½ÅÀ庴
  • rheumatic disease
    ·ù¸¶Æ¼½ºº´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • chain termination method
    ¿¬¼âÁ¾·á¹ý
  • chromosome chain
    ¿°»öü»ç½½, ¿°»öü°í¸®
  • closed chain
    ´ÝÈù»ç½½
  • cold chain
    Àú¿ÂÀ¯Áö¸Á
  • food chain
    ¸ÔÀ̻罽
  • hemolytic chain
    ¿ëÇ÷»ç½½
  • joining chain
    ¿¬°á»ç½½
  • lateral chain
    (¢¡side chain) °ç»ç½½
  • light chain
    °¡º­¿î»ç½½, °æ¼â
  • nuclear chain
    Çٻ罽
  • open chain
    ¿­¸°»ç½½
  • open-chain compound
    (¢¡open chain) ¿­¸°»ç½½
  • oxidative chain
    »êÈ­¿¬¼â
  • respiratory chain
    È£Èí»ç½½
  • reverberating chain
    ¹ÝÇâ»ç½½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • heavy hydrocarbon
    Áßźȭ¼ö¼Ò(ñì÷©ûùâ©áÈ).
  • heavy hydrogen =ducterium
    Áß¼ö¼Ò(ñìâ©áÈ).
  • heavy ion
    ÁßÀÌ¿Â
  • heavy ion irradiation
    ÁßÀÌ¿ÂÁ¶»ç
  • heavy magnesia
    Áß(ñì)¸¶±×³×½Ã¾Æ.
  • heavy magnesium carbonate
    Áß(ñì)ź»ê¸¶±×³×½·.
  • heavy metal antagonist
    Á߱ݼӱæÇ×¾à(̡˻ËÛ˻̰Ëâ).
  • heavy metal antagonist
    Á߱ݼӱæÇ×¾à(ñìÐÝáÕÑÏù÷å·).
  • heavy metal excretion
    Á߱ݼӹ輳(̡˻ËÛËÑËÛ).
  • heavy metal excretion
    Á߱ݼӹ輳(ñìÐÝáÕÛÉàÜ).
  • heavy metal intoxication
    Á߱ݼÓÁßµ¶(ÊÙÌ¡ËÄ).
  • heavy metal intoxication
    Á߱ݼÓÁßµ¶(¡­ñéÔ¸).
  • heavy metal poisoning
    Á߱ݼÓÁßµ¶(ÊÙÌ¡ËÄ).
  • heavy metal poisoning
    Á߱ݼÓÁßµ¶(¡­ñéÔ¸).
  • heavy oil
    ÁßÀ¯(ñìêú).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • heavy metal excretion
    Á߱ݼӹ輳(ñìÐÝáÕÛÉàÜ).
  • heavy metal intoxication
    Á߱ݼÓÁßµ¶(ÊÙÌ¡ËÄ).
  • heavy metal intoxication
    Á߱ݼÓÁßµ¶(¡­ñéÔ¸).
  • heavy metal poisoning
    Á߱ݼÓÁßµ¶(ÊÙÌ¡ËÄ).
  • heavy metal poisoning
    Á߱ݼÓÁßµ¶(¡­ñéÔ¸).
  • heavy oil
    ÁßÀ¯(ñìêú).
  • heavy oxygen
    Áß»ê¼Ò(ñìß«áÈ).
  • heavy particle
    ÁßÀÔÀÚ(ñìí£í­).
  • heavy particle
    ÁßÀÔÀÚ
  • heavy solution
    Áß¾×(ñìäû).
  • heavy water
    Áß¼ö(ñìâ©).
  • poisoning by heavy metals
    Á߱ݼÓÁßµ¶(̡˻ËÛÌ¡ËÄ).
  • poisoning by heavy metals
    Á߱ݼÓÁßµ¶(ñìÐÝáÕñéÔ¸).
  • alpha (¥á) globulin
    ¾ËÆÄ±Û·ÎºÒ¸°
  • alpha (¥á)-interferon
    ¾ËÆÄÀÎÅÍÆä·Ð
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Cushing's disease
    Äí½Ì Áúȯ(òðü´)
  • cytogenetic disease
    ¼¼Æ÷À¯ÀüÁúȯ(á¬øàë¶îîòðü´)
  • deficiency disease
    °áÇÌ Áúȯ(ÌÀù¹òðü´)
  • Fabry's disease
    ÆÄºê¸® Áúȯ (òðü´)
  • Farber's disease
    ÆÄ¾Æ¹ö Áúȯ(òðü´)
  • Forbe`s disease
    Æ÷ºê Áúȯ(òðü´)
  • Gaucher's disease
    °í¿À¼Å Áúȯ(òðü´)
  • genetic disease
    À¯Àü Áúȯ(ë¶îîòðü´)
  • Gilbert's disease
    ±æ¹öÆ® Áúȯ(òðü´)
  • glycogen storage disease
    ±Û¶óÀÌÄÚÀü ÀúÀå Áúȯ(îÍíúòðü´)
  • Hartnup's disease
    ÇÏÆ®³Ò Áúȯ(òðü´)
  • Hers' disease
    ¿¡¸£½º Áúȯ(òðü´)
  • I-cell disease
    I-¼¼Æ÷ Áúȯ(á¬øàòðü´)
  • immune deficincy disease
    ¸é¿ª °áÇÌ Áúȯ(Øóæ¹ÌÀù¹òðü´)
  • Krabbe's disease
    Å©¶óº£Áúȯ(òðü´)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • hematopoietic disease
    Á¶Ç÷¼ºÁúȯ
  • hereditary disease
    À¯Àüº´
  • Hodgkin's disease
    È£ÁîŲº´
  • hyaline membrane disease
    À¯¸®Áú¸·º´
  • hypertensive vascular disease
    °íÇ÷¾Ð¼ºÇ÷°üÁúȯ
  • inherited disease
    À¯Àüº´
  • ischemic heart disease
    ÇãÇ÷¼º ½ÉÁúȯ
  • Letterer-Siwe disease
    ·¹Å×·¯-½Ã¿þº´
  • marble bone disease
    ´ë¸®¼®°ñº´
  • metabolic disease
    ´ë»ç¼ºÁúȯ
  • mitral valvular disease
    ½Â¸ðÆÇ¸·Áúȯ
  • neoplastic disease
    Á¾¾ç¼ºÁúȯ
  • neuromuscular disease
    ½Å°æ±ÙÀ° Áúȯ
  • Niemann-Pick disease
    ´ÏÀ̸¸-ÇȺ´
  • nutritional deficiency disease
    ¿µ¾ç°áÇÌÁõ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
HCG, hCG Human Chorionic Gonadotropin; »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó
  1. Placental Glycoprotein Hormone
&nbs...
AH   1) Atrial Hypertrophy
  2) Anti-Hyaluronidase
  3) Amyloid imm...
e Greek letter epsilon; heavy chain of IgE; permittivity; specific absorptivity
Fd the amino-terminal portion of the heavy chain of an immunoglobulin molecule; ferredoxin
FTH ferritin heavy chain; fracture threshold
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MHC Myosin heavy chain
MyHC Myosin heavy chain
SM MHC Smooth muscle myosin heavy chain
VH V heavy chain
beta MHC beta myosin heavy chain
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • alpha
    ¥á
    chain
  • alpha 1-adrenergic blocker
    ¾ËÆÄ 1-¾Æµå·¹³¯¸°¼º Â÷´Ü
  • alpha 2 agonist clonidine
    ¾ËÆÄ 2 ÀÛµ¿ Ŭ·Î´Ïµò
  • alpha 2 binding
    ¾ËÆÄ 2 °áÇÕ
  • alpha adrenergic antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸° ±æÇ×Á¦
  • alpha amylose
    ¾ËÆÄ-¾Æ¹Ð·Î½º
    °ÅÀÇ ¾Æ¹Ð·Î½ºÀÎ ÀüºÐÀÇ ÁÖ¼ººÐÀ¸·Î¼­, ±Û·çÄÚ½º°¡ a-1,4 °áÇÕÀ¸·Î Á÷¼â»ó °áÇÕÇÑ °Í.
  • alpha efferent motor neuron
    ¾ËÆÄ ¿ø½É ¿îµ¿ ´º¿ì·±, ¾ËÆÄ ¿ø½É¼º ¿îµ¿ ´º·±
  • alpha fiber
    ¾ËÆÄ ¼¶À¯, ¾ËÆÄ ½Å°æ¼¶À¯
  • alpha hemolysis
    ¾ËÆÄ ¿ëÇ÷
  • alpha motorneuron
    ¾ËÆÄ ¿îµ¿ ´º¿ì·Ð
  • alpha ray
    ¾ËÆÄ ¼±
  • alpha streptococus
    ¾ËÆÄÇü ¿¬¼â ±¸±Õ
  • alpha toxin
    ¾ËÆÄ µ¶¼Ò
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸° ¼ö¿ëü
  • alpha-amylase
    ¾ËÆÄ-¾Æ¹Ð¶óÁ¦
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
NAD 3 alpha-hydroxy-5 alpha-pregnan-20-one-oxidoreductase <enzyme> From rat liver microsomes
Registry number: EC 1.1.1.-
Synonym: nad-3-hp-20-oor
(26 Jun 1999)
1,4-alpha-d-glucan 6-alpha-d-glucosyltransferase A glucosyltransferase that transfers an alpha-glucosyl residue in a 1,4-alpha-glucan to the primary hydroxyl group of glucose in a 1,4-alpha-glucan.
See: 1,4-alpha-d-glucan branching enzyme.
Synonym: oligoglucan-branching glycosyltransferase.
(05 Mar 2000)
1,4-alpha-glucan 6-alpha-glucosyltransferase <enzyme> From aspergillus niger and oryzae
Registry number: EC 2.4.1.24
(26 Jun 1999)
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid <chemical> A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of vasopressin and activation of phospholipase c.
Pharmacological action: vasoconstrictor agents.
Chemical name: 5-Heptenoic Acid, 7-(6-(3-Hydroxy-1-Ocentyl)-2-Oxabicyclo(2.2.1)hept-5-yl)-, (1R-(1alpha,4alpha,5 beta(Z),6alpha(1E,3S*)))-
(12 Dec 1998)
5 alpha-3 alpha-hydroxysteroid dehydrogenase <enzyme> Androsterone can be substrate
Registry number: EC 1.1.1.50
Synonym: 3 alpha-hydroxysteroid dehydrogenase, 3 alpha-hydroxysteroid oxidoreductase, 3 oc-hydroxysteroid dehydrogenase
(26 Jun 1999)
5 alpha-androstane-3 beta,17 beta-diol 6 alpha-hydroxylase <enzyme> Requires NADPH, found in rat prostatic microsomes
Registry number: EC 1.14.13.-
Synonym: artdl 6 alpha-hydroxylase
(26 Jun 1999)
5 alpha-androstane 3 beta,17 beta-diol 7 alpha-hydroxylase <enzyme> Requires NADPH, found in rat prostate microsomes
Registry number: EC 1.14.13.-
Synonym: artdl 7 alpha-hydroxylase
(26 Jun 1999)
5 alpha-dihydroprogesterone 3 alpha-hydroxysteroid oxidoreductase <enzyme> Catalyses conversion of 5 alpha-dihydroprogesterone to 3 alpha -hydroxy-5 alpha-pregnane-20-one
Registry number: EC 1.1.1.-
Synonym: 5-dp-3 alpha-hso, NADPH-5 alpha-dihydroprogesterone 3 alpha-hydroxysteroid oxidoreductase, alpha-hsor
(26 Jun 1999)
5 beta-cholestane-3 alpha,7 alpha-diol 26-hydroxylase <enzyme> Nadp-dependent
Registry number: EC 1.14.13.-
(26 Jun 1999)
7 alpha-hydroxy-4-cholesten-3-one-12 alpha monooxygenase <enzyme> Liver microsomal enzyme active in conversion of cholesterol to cholic acid; introduces a 12 alpha-hydroxyl group into the steroid nucleus of cholesterol
Registry number: EC 1.14.99.-
Synonym: 7-hco-monooxygenase, hco 12 alpha-hydroxylase
(26 Jun 1999)
A chain A polypeptide component of insulin containing 21 amino acyl residues, beginning with a glycyl residue (NH2-terminus); insulin is formed by the linkage of an A chain to a B chain by two disulfide bonds; the amino-acid composition of the A chain is a function of species.
Synonym: glycyl chain.
In general, one of the polypeptides in a multiprotein complex.
(05 Mar 2000)
amino acids, branched-chain Amino acids which have a branched carbon chain.
(12 Dec 1998)
B chain A polypeptide component of insulin containing 30 amino acyl residues, beginning with a phenylalanyl residue (NH2-terminus); insulin is formed by the linkage of a B chain to an A chain by two disulfide bonds; the amino-acid composition of the B chain is a function of species.
Synonym: phenylalanyl chain.
(05 Mar 2000)
behaviour chain Related behaviours in a series in which each response serves as a stimulus for the next response.
(05 Mar 2000)
branched chain acyl-CoA oxidase <enzyme> Enzyme from human liver peroxisomes acts on both 2-methyl branched fatty acyl- and bile acid-CoA intermediates, unlike rat liver peroxisomes which have separate enzymes for branched chain fatty acids (pristanoyl-CoA) and bile acid-CoA; involved in beta-oxidation of fatty acids and bil
Registry number: EC 1.3.3.-
Synonym: 2-methyl-branched chain acyl-CoA oxidase, hbrcacox
(26 Jun 1999)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • heavy rock
    =progressive rock
  • heavy sea
    °Ý¶û
  • heavy sky
    È帰 ÇÏ´Ã
  • heavy spar
    ÁßÁ¤¼®(barite)
  • heavy swell
    ¹Ù´ÙÀÇ ½ÉÇÑ ³î;dzä(ŵµ)°¡ ´ç´çÇÑ ¸í»ç
  • heavy traffic
    ´ëÇüÀÚµ¿Â÷;ÀÚµ¿Â÷ÀÇ È«¼ö
  • heavy water
    Áß¼ö A
  • heavy wet
    ¸Æ¾Æ ¾çÁ¶ÁÖ
  • top-heavy
    ¸Ó¸®°¡ Å«
  • chain
    »ç½½
  • Gunter's chain
    °ÇÅÍ Ãø·®¿ë »ç½½(±æÀÌ 66ÇÇÆ®)
  • Markov(Markoff) chain
    ¸¶¸£ÄÚÇÁ ¿¬¼â
  • chain
    ¼è»ç½½;ÀÏ·Ã;¿¬¼â;(¹æ¼ÛÀÇ)³×Æ®¿öÅ©;¸ñ°ÉÀÌ;°í¸®ÁÙ(°üÁ÷ÀÇ Ç¥½Ã·Î¼­ ¸ñ¿¡ °Å´Â);(ÀÚÀü°ÅÀÇ)üÀÎ;µµ¾îüÀÎ;(¿¬¼â °æ¿µÀÇ ÀºÇà.±ØÀå.È£ÅÚ µîÀÇ)üÀÎ(Á¡);¿¬¼âÁ¡;(»ç½½ÀÌ ´Þ¸°)Â÷²¿;Á·¼â;±¼·¹;¼Ó¹Ú;±¸±Ý;Ãø¼â;¤²Ã¼ÀÎ;ȸ·Î;¼è»ç½½ÅºÈ¯;¿¬¼â(¿øÀÚÀÇ);´é»ç½½;(µ¿¹° µîÀ»)»ç½½·Î ¸Å
  • chain armor
    CHAIN MAIL
  • chain belt
    (ÀÚÀü°Å µîÀÇ)Åé´Ï¹ÙÄû¿ë üÀÎ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á